


CLAIMS

1. A compound of formula (1):



5

or a pharmaceutically acceptable salt thereof, wherein

R¹ is optionally-substituted C₁₋₆ alkyl, optionally-substituted C₃₋₁₀ cycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl group; and

R² is halogen atom, cyano, C₁₋₆ alkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, C₁₋₆ alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 or 2 the same or different C₁₋₆ alkyl groups.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein

20 R¹ is

(1) C₁₋₆ alkyl which may be optionally substituted with 1 to 3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, C₃₋₇ cycloalkyl, and C₁₋₆ alkoxy,

25 (2) C₃₋₁₀ cycloalkyl which may be optionally substituted with 1 to 4 the same or different substituents selected from the group consisting of halogen atom, hydroxy,

cyano, C₁₋₆ alkyl which may be optionally substituted with 1 to 3 the same or different halogen atom or C₁₋₆ alkoxy, C₁₋₆ alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atom or C₁₋₆ alkoxy, and amino
5 which may be optionally substituted with 1 or 2 the same or different C₁₋₆ alkyl, or

(3) 5- to 10-membered saturated or partially-unsaturated heterocyclyl group which may be optionally substituted with 1 to 4 the same or different substituents
10 selected from the group consisting of halogen atom, hydroxy, cyano, C₁₋₆ alkyl which may be optionally substituted with 1 to 3 the same or different halogen atom or C₁₋₆ alkoxy, C₁₋₆ alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atom or C₁₋₆ alkoxy, and amino
15 which may be optionally substituted with 1 or 2 the same or different C₁₋₆ alkyl.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein

20 R¹ is

(1) C₃₋₇ cycloalkyl which may be optionally substituted with 1 to 4 the same or different substituents selected from the group consisting of halogen atom, and C₁₋₆ alkyl which may be optionally substituted with 1 to 3 the same or
25 different halogen atom or C₁₋₆ alkoxy, or

(2) 5- or 6-membered saturated or partially-unsaturated heterocyclyl group which may be optionally substituted with 1 to 4 the same or different substituents selected from the group consisting of halogen atom, and C₁₋₆
30 alkyl which may be optionally substituted with 1 to 3 the same or different halogen atom or C₁₋₆ alkoxy.

4. The compound of claim 1, or a pharmaceutically

acceptable salt thereof, wherein R¹ is C₃₋₇ cycloalkyl which may be optionally substituted with 1 to 4 fluorine atoms, or 5- or 6-membered saturated or partially-unsaturated heterocyclyl group which may be optionally substituted with
5 1 to 4 fluorine atoms.

5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is cyclohexyl which may be optionally substituted with 1 to 4 fluorine atoms,
10 tetrahydropyranyl, tetrahydrofuryl, dihydropyranyl, or dihydrofuryl.

6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is difluorocyclohexyl,
15 or tetrahydropyranyl.

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R² is halogen atom, or C₁₋₆ alkyl which may be optionally substituted with 1 to 3 the
20 same or different halogen atoms.

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R² is C₁₋₄ alkyl which may be optionally substituted with 1 to 3 fluorine atoms.
25

9. The compound of claim 1, which is selected from the group consisting of:

4,4-difluoro-N-(2-{4-[6-(trifluoromethyl)pyridin-2-yl]piperidin-1-yl}ethyl)cyclohexane-carboxamide,

30 N-{2-[4-(6-methylpyridin-2-yl)piperidin-1-yl]ethyl}-tetrahydro-2H-pyran-4-carboxamide,

2,2-dimethyl-N-(2-{4-[6-(trifluoromethyl)pyridin-2-yl]piperidin-1-yl}ethyl)propanamide, and

N-(2-{4-[6-(trifluoromethyl)pyridin-2-yl]piperidin-1-yl}ethyl)-tetrahydro-2H-pyran-4-carboxamide,
or a pharmaceutically acceptable salt thereof.

- 5 10. The compound of claim 1, which is 2,2-dimethyl-N-(2-{4-[6-(trifluoromethyl)pyridin-2-yl]piperidin-1-yl}ethyl)propanamide, or a pharmaceutically acceptable salt thereof.
- 10 11. A medicament comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable excipient, additive and/or carrier.
- 15 12. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease or disorder selected from the group consisting of generalized anxiety disorder, major depression, obsessive-compulsive disorder, Parkinson's
20 disease, and Rett syndrome.
13. The compound of claim 1 or a pharmaceutically acceptable salt thereof for use in the treatment of a disease or disorder selected from the group consisting of
25 generalized anxiety disorder, major depression, obsessive-compulsive disorder, Parkinson's disease, and Rett syndrome.
14. A medicament comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one
30 other medicament selected from drugs classified as an antianxiety drug or an antidepressant drug.
15. The medicament of claim 14, wherein the antianxiety

drug is a selective serotonin reuptake inhibitor.

16. The medicament of claim 15, wherein the selective serotonin reuptake inhibitor is at least one drug selected from the group consisting of sertraline, escitalopram, fluvoxamine, fuoxetine, paroxetine, clomipramine, and pharmaceutically acceptable salts thereof.

17. The medicament of claim 14, wherein the antidepressant drug is a serotonin reuptake inhibitor.

18. The medicament of claim 17, wherein the serotonin reuptake inhibitor is at least one drug selected from the group consisting of milnacipran, duloxetine, venlafaxine, amoxapine, clomipramine, nortriptyline, imipramine, vortioxetine, and pharmaceutically acceptable salts thereof.

19. The use of claim 12 or the compound or a pharmaceutically acceptable salt thereof for use according to claim 13, wherein the compound is 4,4-difluoro-N-(2-{4-[6-(trifluoromethyl)pyridin-2-yl]piperidin-1-yl}ethyl)cyclohexane-carboxamide, or a pharmaceutically acceptable salt thereof.

20. The use of claim 12 or the compound or a pharmaceutically acceptable salt thereof for use according to claim 13, wherein the compound is N-{2-[4-(6-methylpyridin-2-yl)piperidin-1-yl]ethyl}-tetrahydro-2H-pyran-4-carboxamide, or a pharmaceutically acceptable salt thereof.

21. The use of claim 12 or the compound or a pharmaceutically acceptable salt thereof for use according

to claim 13, wherein the compound is N-(2-{4-[6-(trifluoromethyl)pyridin-2-yl]piperidin-1-yl}ethyl)-tetrahydro-2H-pyran-4-carboxamide, or a pharmaceutically acceptable salt thereof.

5

22. The use of claim 12 or the compound or a pharmaceutically acceptable salt thereof for use according to claim 13, wherein the disease or disorder is generalized anxiety disorder, major depression, or obsessive-compulsive disorder.

10

23. The use or the compound or a pharmaceutically acceptable salt thereof for use according to claim 19, wherein the disease or disorder is generalized anxiety disorder, major depression, or obsessive-compulsive disorder.

15

24. The use or the compound or a pharmaceutically acceptable salt thereof for use according to claim 20, wherein the disease or disorder is generalized anxiety disorder, major depression, or obsessive-compulsive disorder.

20

25. The use or the compound or a pharmaceutically acceptable salt thereof for use according to claim 21, wherein the disease or disorder is generalized anxiety disorder, major depression, or obsessive-compulsive disorder.

25

26. The compound of claim 1, which is selected from the group consisting of:

30

4,4-difluoro-N-(2-{4-[6-(trifluoromethyl)pyridin-2-yl]piperidin-1-yl}ethyl)cyclohexane-carboxamide,

N-{2-[4-(6-methylpyridin-2-yl)piperidin-1-yl]ethyl}-
tetrahydro-2H-pyran-4-carboxamide, and

N-(2-{4-[6-(trifluoromethyl)pyridin-2-yl]piperidin-1-
yl}ethyl)-tetrahydro-2H-pyran-4-carboxamide,

5 or a pharmaceutically acceptable salt thereof.

27. The compound of claim 26, which is 4,4-difluoro-N-(2-
{4-[6-(trifluoromethyl)pyridin-2-yl]piperidin-1-
yl}ethyl)cyclohexane-carboxamide, or a pharmaceutically
10 acceptable salt thereof.

28. The compound of claim 26, which is N-{2-[4-(6-
methylpyridin-2-yl)piperidin-1-yl]ethyl}-tetrahydro-2H-
pyran-4-carboxamide, or a pharmaceutically acceptable salt
15 thereof.

29. The compound of claim 26, which is N-(2-{4-[6-
(trifluoromethyl)pyridin-2-yl]piperidin-1-yl}ethyl)-
tetrahydro-2H-pyran-4-carboxamide, or a pharmaceutically
20 acceptable salt thereof.